{"id":19232,"date":"2026-06-11T00:00:00","date_gmt":"2026-06-10T22:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=c3362870a39457edaece0f9bc50e3422"},"modified":"2026-06-11T00:00:00","modified_gmt":"2026-06-10T22:00:00","slug":"regn-investors-have-opportunity-to-join-regeneron-pharmaceuticals-inc-fraud-investigation-with-the-schall-law-firm","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=19232","title":{"rendered":"REGN Investors Have Opportunity to Join Regeneron Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm"},"content":{"rendered":"

LOS ANGELES--(BUSINESS WIRE)--$REGN<\/a>--The Schall Law Firm<\/a>, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (\u201cRegeneron\u201d or \u201cthe Company\u201d) (NASDAQ: REGN<\/a>) for violations of the securities laws.<\/p><\/a><\/a>

The investigation focuses on whether the Company issued false and\/or misleading statements and\/or failed to disclose information pertinent to investors. Regeneron issued a press release on May 15, 2026, revealing that \u201cresults from the Phase 3 trial evaluating two dose levels of fianlimab (LAG-3 inhibitor) in combination with cemiplimab (PD-1 inhibitor) as a first-line treatment for patients with unresectable locally advanced or metastatic melanoma\u201d failed to achieve statistical significance \u201cfor the primary endpoint of improvement in progression-free survival (PFS) compared to pembrolizumab (PD-1 inhibitor) monotherapy.\u201d Based on this news, shares of Regeneron fell by more than 9.8% on the next day.<\/p>

If you are a shareholder who suffered a loss, click here to participate<\/a>.<\/p>

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com<\/a>, or by email at bschall@schallfirm.com<\/a>.<\/p>

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.<\/p>

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.<\/p> Contacts<\/b>

The Schall Law FirmBrian Schall, Esq.310-301-3335info@schallfirm.com<\/a>www.schallfirm.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

LOS ANGELES–(BUSINESS WIRE)–$REGN–The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (\u201cRegeneron\u201d or \u201cthe Company\u201d) (NASDAQ: REGN) f…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-19232","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/19232","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19232"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/19232\/revisions"}],"predecessor-version":[{"id":19233,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/19232\/revisions\/19233"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19232"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19232"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19232"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}